Myriad Genetics (MYGN) Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View MYGN analyst ratings or view top-rated stocks.

5 brokers have issued 1 year target prices for Myriad Genetics' shares. Their MYGN share price forecasts range from $17.00 to $28.00. On average, they predict the company's stock price to reach $24.20 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price.
View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts.

Myriad Genetics' stock was trading at $14.51 on January 1st, 2023. Since then, MYGN stock has increased by 15.7% and is now trading at $16.79.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our MYGN earnings forecast.

Myriad Genetics, Inc. (NASDAQ:MYGN) released its earnings results on Thursday, August, 3rd. The company reported ($0.08) earnings per share for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $183.50 million for the quarter, compared to analyst estimates of $187.16 million. Myriad Genetics had a negative net margin of 35.51% and a negative trailing twelve-month return on equity of 9.43%. The business's revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.06) EPS.

ETFs with the largest weight of Myriad Genetics (NASDAQ:MYGN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).SPDR S&P 600 Small Cap ETF (SLY).

Myriad Genetics issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of -$0.36--$0.24 for the period, compared to the consensus EPS estimate of -$0.32. The company issued revenue guidance of $730.00 million-$750.00 million, compared to the consensus revenue estimate of $742.12 million.

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MYGN stock can currently be purchased for approximately $16.79.

Myriad Genetics (NASDAQ:MYGN) has a market capitalization of $1.37 billion and generates $678.40 million in revenue each year. The company earns $-112,000,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

The company employs 2,600 workers across the globe.

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The official website for the company is www.myriad.com. The company can be reached via phone at (801) 584-3600, via email at sgleason@myriad.com, or via fax at 801-584-3640.